Perennial Investment Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,373 shares of the company’s stock after purchasing an additional 71 shares during the quarter. Perennial Investment Advisors LLC’s holdings in Johnson & Johnson were worth $772,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of JNJ. Nordwand Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $785,273,000. Savant Capital LLC raised its position in shares of Johnson & Johnson by 8,568.8% in the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock valued at $29,637,000 after purchasing an additional 3,588,251 shares during the period. Edmp Inc. increased its position in Johnson & Johnson by 17,222.9% during the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after acquiring an additional 3,204,658 shares during the period. Vanguard Group Inc. increased its position in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. Finally, GQG Partners LLC increased its position in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. Institutional investors own 67.94% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on JNJ. Piper Sandler dropped their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Raymond James dropped their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. Finally, Guggenheim initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Insider Buying and Selling
Johnson & Johnson Stock Up 0.3 %
Shares of NYSE:JNJ opened at $158.91 on Monday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The company’s fifty day moving average is $159.70 and its 200-day moving average is $166.20. The company has a market capitalization of $412.96 billion, a PE ratio of 33.24, a P/E/G ratio of 2.71 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. During the same quarter in the previous year, the company earned $2.67 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio is 94.56%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Warren Buffett Boosts Occidental Stake, Adds 3.46 Million Shares
- What’s Behind The Recent Meteoric Rise Of Tingo Group
- Is PulteGroup Overbought After Double-Digit Gains?
- Netflix Stock Just Had Its Largest Intraday Gain Since 2022
- Analyst Flags Concerns About P&G Growth Despite Earnings Beat
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
